Article

Surgical Updates from the 32nd Annual Miami Breast Cancer Conference

Debu Tripathy, CURE's editor-in-chief, reports on surgical research updates announced at the Miami Breast Cancer Conference held in late February.

Debu Tripathy, CURE's editor-in-chief and chair of the breast medical oncology department at MD Anderson Cancer Center, reports on surgical research updates announced at the Miami Breast Cancer Conference held in late February.

Emerging, and sometimes controversial, approaches to surgery and radiation treatment for breast cancer was discussed.

Six weeks of radiation therapy after lumpectomy is a traditional strategy of breast cancer treatment. A new approach that has been tested over the past 10 years that reduces the duration of radiation, called hypofractioned radiation, may be as effective and more convenient for patients. Current research is looking into who would be a prime candidate for this new form of radiation.

Another area of radiation is for higher-risk cancers and extending the area of radiation that would include the regional lymph nodes under the arms, near the collarbone and the chest bone.

A new guideline for surgical margins during breast cancer surgery was also discussed during the conference. Surgeons want to remove all cancer so that the tissue removed has "clear margins."

"The big question has been how close should the margin be for us to recommend whether the surgeon should go back in and take more tissue," he says, or other strategies.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content